ABSTRACT
Intravenous immunoglobulin (IVIG), initially used as replacement therapy in primary and secondary antibody deficiency syndromes, has recently acquired an important role in the treatment of some dysimmune pathologies, including diseases of the central and peripheral nervous systems1. Compared with other immunoacting treatments, IVIG is characterized by a good safety profile. The main risk consists of the transmission of infectious agents that can only be excluded if the manufacturing process is optimal.
